Abstract
Systemic treatment modalities for eradication of multiple therapy resistant genital warts are so far not available. In this study laser treated patients with multiple genital warts received postoperatively either interferon alpha-2b subcutaneously (s.c.) 5 x 10(6) IU or matching placebo three times weekly for four weeks. At the conclusion of the study, 6-8 weeks after discontinuation of therapy, a significantly higher cure rate was found in the group of interferon-treated patients (14 of 27 (52%) patients cured) than among placebo treated patients (5 of 22 (23%) patients cured) (p less than 0.05). The side effects of fever, chills, myalgia, headache and leukopenia occurred more commonly in the interferon treated group than in the placebo group. However, only three of 32 patients discontinued interferon therapy because of side effects. We conclude that the addition of s.c. administered interferon alpha-2b to laser treated patients with chronic therapy resistant genital warts is fairly well tolerated and that it significantly enhances the chance of eliminating the disease.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Benedetti Panici P., Scambia G., Baiocchi G., Perrone L., Pintus C., Mancuso S. Randomized clinical trial comparing systemic interferon with diathermocoagulation in primary multiple and widespread anogenital condyloma. Obstet Gynecol. 1989 Sep;74(3 Pt 1):393–397. [PubMed] [Google Scholar]
- Eron L. J., Judson F., Tucker S., Prawer S., Mills J., Murphy K., Hickey M., Rogers M., Flannigan S., Hien N. Interferon therapy for condylomata acuminata. N Engl J Med. 1986 Oct 23;315(17):1059–1064. doi: 10.1056/NEJM198610233151704. [DOI] [PubMed] [Google Scholar]
- Erpenbach K., Derschum W., von Vietsch H. Adjuvant-systemische Interferon-alpha 2B-Behandlung bei therapieresistenten anogenitalen Condylomata acuminata. Urologe A. 1990 Jan;29(1):43–45. [PubMed] [Google Scholar]
- Gross G., Ikenberg H., Roussaki A., Drees N., Schöpf E. Systemic treatment of condylomata acuminata with recombinant interferon-alpha-2a: low-dose superior to the high-dose regimen. Chemotherapy. 1986;32(6):537–541. doi: 10.1159/000238464. [DOI] [PubMed] [Google Scholar]
- Larsen J., Petersen C. S. The patient with refractory genital warts in the STD-clinic. Treatment failure with CO2-laser. Dan Med Bull. 1990 Apr;37(2):194–195. [PubMed] [Google Scholar]
- Olsen E. A., Kelly F. F., Vollmer R. T., Buddin D. A., Weck P. K. Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata. J Am Acad Dermatol. 1989 Jun;20(6):1023–1030. doi: 10.1016/s0190-9622(89)70127-4. [DOI] [PubMed] [Google Scholar]
- Perrillo R. P., Schiff E. R., Davis G. L., Bodenheimer H. C., Jr, Lindsay K., Payne J., Dienstag J. L., O'Brien C., Tamburro C., Jacobson I. M. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990 Aug 2;323(5):295–301. doi: 10.1056/NEJM199008023230503. [DOI] [PubMed] [Google Scholar]
- Reichman R. C., Oakes D., Bonnez W., Greisberger C., Tyring S., Miller L., Whitley R., Carveth H., Weidner M., Krueger G. Treatment of condyloma acuminatum with three different interferons administered intralesionally. A double-blind, placebo-controlled trial. Ann Intern Med. 1988 May;108(5):675–679. doi: 10.7326/0003-4819-108-5-675. [DOI] [PubMed] [Google Scholar]
- Zachariae H., Larsen P. M., Søgaard H. Recombinant interferon alpha-2A (Roferon-A) in a case of Buschke-Löwenstein giant condyloma. Dermatologica. 1988;177(3):175–179. doi: 10.1159/000248538. [DOI] [PubMed] [Google Scholar]